Contributions
Abstract: 68
Type: Educational Session
Abstract Category: N/A
The early prediction of prognosis and of response to treatment are central goals of clinical research, and they are particularly relevant in the field of Multiple Sclerosis (MS) research. MS, in fact, is a disease with a long-term clinical course and the rate of accumulation of disability is hardly predictable at the disease onset. Moreover, since the range of treatments now available for MS is quickly broadening, it would be of crucial importance for clinicians to be able to predict the individual patient's response to therapy in order to make quick optimal therapeutic decisions. Finally, an early prediction of the long term treatment effect on disability accumulation would be important to shorten the duration of clinical trials in MS, that should last at least 2-3 years when the primary endpoint is the disability worsening.
To allow an early prediction of prognosis and response to treatment we would need markers, that can be classified in three groups, according to their role:
- the early prediction of prognosis requires the definition of prognostic factors
- the early detection of response to treatments requires the definition of markers of response to treatment or treatment effect modifiers
- the early determination of treatment efficacy requires the definitions of surrogate markers.
Disclosure: MPS received consulting fees from Novartis, Biogen, TEVA, Roche, Genzyme, GeNeuro, Merck Serono, Medday, Actelion
Abstract: 68
Type: Educational Session
Abstract Category: N/A
The early prediction of prognosis and of response to treatment are central goals of clinical research, and they are particularly relevant in the field of Multiple Sclerosis (MS) research. MS, in fact, is a disease with a long-term clinical course and the rate of accumulation of disability is hardly predictable at the disease onset. Moreover, since the range of treatments now available for MS is quickly broadening, it would be of crucial importance for clinicians to be able to predict the individual patient's response to therapy in order to make quick optimal therapeutic decisions. Finally, an early prediction of the long term treatment effect on disability accumulation would be important to shorten the duration of clinical trials in MS, that should last at least 2-3 years when the primary endpoint is the disability worsening.
To allow an early prediction of prognosis and response to treatment we would need markers, that can be classified in three groups, according to their role:
- the early prediction of prognosis requires the definition of prognostic factors
- the early detection of response to treatments requires the definition of markers of response to treatment or treatment effect modifiers
- the early determination of treatment efficacy requires the definitions of surrogate markers.
Disclosure: MPS received consulting fees from Novartis, Biogen, TEVA, Roche, Genzyme, GeNeuro, Merck Serono, Medday, Actelion